Biopril

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biopril

Quick Facts: Biopril (Lisinopril)

Property Description
Active Ingredient Lisinopril (as dihydrate)
Form Oral tablet, Oral solution
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose Cardiovascular support
Origin Synthetic, non-prodrug
Differentiation Nonsulfhydryl structure; long-acting effect

Biopril: Drug Identity and Pharmacological Class

Biopril is a brand name for a pharmaceutical preparation where the active ingredient is Lisinopril. This compound is categorized as an Angiotensin-Converting Enzyme (ACE) Inhibitor. Chemically, it is a synthetic, long-acting dipeptide derivative.

Lisinopril is distinguished by its nonsulfhydryl chemical structure, which supports its long-acting profile. It is a non-prodrug, meaning it does not require metabolic conversion to become active and functions upon ingestion. The role of this medication is to stabilize the Renin-Angiotensin-Aldosterone System (RAAS), a physiological mechanism responsible for maintaining cardiovascular homeostasis.


Composition, Form, and General Purpose

This medication is primarily available as an oral tablet. As a monotherapy, the composition of Biopril features Lisinopril as the sole active ingredient. It is formulated with pharmaceutical excipients—such as microcrystalline cellulose—to facilitate stable and effective oral delivery.

The general purpose of this ACE inhibitor is to modulate the body’s blood pressure regulators. It works by suppressing the production of a specific vasoconstricting hormone, which helps to relax blood vessels and manage fluid volume. This process reduces the workload on the heart and supports cardiovascular efficiency.

What side effects are possible with Biopril?

Possible Side Effects and Safety Information: Biopril (Lisinopril)

The officially documented safety profile for Biopril (Lisinopril), an Angiotensin-Converting Enzyme (ACE) Inhibitor, organizes adverse effects by frequency and the body system affected. These classifications reflect how government regulatory documents communicate the medicine's potential risks.

Frequency-Classified Adverse Reactions

Regulatory labeling classifies certain effects as Common (occurring in 1 to 10 out of 100 people), including dizziness, headache, a dry, persistent cough, fatigue, and hypotension (low blood pressure). Effects classified as Uncommon include rash, vertigo, and taste disturbance.

Serious Adverse Reactions

A critical, but rare, risk documented in regulatory sources is Angioedema, which involves swelling of the face, tongue, glottis, and/or larynx and requires immediate attention. Use of Lisinopril is contraindicated in patients with a history of angioedema related to a previous ACE inhibitor or in those with hereditary angioedema. Cases of Acute Renal Failure and Hepatic Failure are documented as rare or very rare events.

Population and Exposure-Related Safety Notes

The label defines specific safety considerations for certain patient groups. Lisinopril is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal toxicity. Older adults and patients with renal impairment are noted to require particular consideration. Furthermore, the risk of Symptomatic Hypotension is officially documented to be highest following the initial dose or a dosage increase.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the clinical consequences of Biopril overdose as an exaggeration of the drug's intended effects, leading to potentially serious or life-threatening conditions. The primary documented clinical manifestations are severe cardiovascular effects, including profound hypotension (severely low blood pressure) and severe bradycardia (abnormally slow heart rate), which can manifest as significant dizziness and lightheadedness.


Serious Outcomes and Emergency Action

Regulatory documents emphasize the risk of critical outcomes, such as circulatory collapse and acute renal failure. The official instructions are unambiguous: IMMEDIATE medical attention must be sought upon a suspected or known overdose, regardless of initial symptoms. Patients or caregivers must immediately contact a Poison Control Center or emergency services and prepare for transport to a hospital emergency department.


Supportive Management and Monitoring

Management in a controlled medical setting is supportive and symptomatic. Measures often involve correcting hypotension with intravenous fluids and vasopressors, and treating severe bradycardia with agents like atropine, if appropriate. Continuous cardiac monitoring (ECG) is required, along with serial assessment of vital signs and laboratory values (e.g., serum electrolytes, renal function) to observe the patient for an extended period, often 12 to 24 hours, until clinical stability is confirmed. Population-specific notes address the heightened sensitivity of pediatric patients and the prolonged elimination kinetics in patients with pre-existing renal impairment.

Therapeutic Uses of Biopril

What Biopril Treats: Main Uses and Benefits

Biopril (Lisinopril) is commonly used for managing cardiovascular support, addressing specific symptomatic domains and providing essential long-term patient benefits. The medication is primarily indicated for conditions involving symptoms related to systemic imbalance and organ-specific functional stress.

This primary use is relevant in conditions where functional stability becomes affected by elevated systemic pressure. The sustained blood pressure management may assist with reducing the potential for major future cardiovascular events, such as stroke or heart attack, and contributes to easing the overall symptom load.

Biopril is commonly used to help with the management of chronic heart failure where it is relevant for managing symptom clusters that may become intense or disruptive, such as excessive physical fatigue and fluid retention. This use supports patients by contributing to improved comfort during symptomatic periods and may assist with maintaining functional stability.

It is also applied in clinical settings following a heart attack to manage symptoms linked to organ-specific functional stress. For patients dealing with both hypertension and Type 2 Diabetes, this use may be part of symptomatic management to slow the progression of diabetic kidney disease.


Quick Fact: Relief for Cardiovascular Stress
Core Symptomatic Domain Managing symptoms related to systemic imbalance and elevated vascular pressure.
Typical Clinical Scenario Long-term maintenance therapy for chronic conditions where sustained support is needed.
Patient Benefit Focus Supports patients by easing the overall systemic burden and contributing to functional stability.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Biopril

Biopril's eligibility profile is strictly defined by regulatory documents, outlining groups for whom the medicine is contraindicated, restricted, or where use is not established. This information is non-advisory and derived from official government labeling.

Contraindicated Populations (Must Not Use) Use Not Established / Not Recommended
Patients with a history of angioedema related to any ACE inhibitor. Children under 6 years of age.
Patients with hereditary or idiopathic angioedema. Pediatric patients with low Glomerular Filtration Rate (GFR).
Use in the second and third trimesters of pregnancy. Women who are breastfeeding/lactating.
Concomitant use with a neprilysin inhibitor or within 36 hours of taking one.
Concomitant use with aliskiren in patients with diabetes mellitus.

Restricted or Conditional Use:

Use is limited and requires special caution and monitoring for specific patient groups. Patients with impaired renal function (Creatinine Clearance <30 mL/min) or hepatic impairment require a reduced initial dose and close medical oversight, as their condition affects the processing and safety of the medication. Eligibility is established only for adults and children ge 6 years of age for the labeled indication.

What should I know about interactions with other medicines?

Biopril Interactions with other medicines and products

Certain combinations of medicines with Biopril (Lisinopril) are either restricted or contraindicated as documented in official regulatory labeling.


Contraindicated Combinations

Interacting Substance/Class Official Interaction Classification
Sacubitril/Valsartan Prohibited for concomitant use (36-hour separation rule required).
Aliskiren or ARBs Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment.

️ Clinically Significant Interactions

Co-administration with other agents may lead to altered physiological effects or modified drug exposure, as explicitly stated by regulatory bodies:

  • Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride), Potassium Supplements, and Salt Substitutes containing potassium: Significant risk of Hyperkalemia (high serum potassium) due to additive effects.
  • Diuretics (e.g., Furosemide): Risk of excessive reduction of blood pressure (symptomatic hypotension).
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): May result in loss of antihypertensive efficacy and an increased risk of renal function deterioration, particularly in the elderly or those with existing renal issues.
  • Lithium: Concomitant use reduces Lithium clearance, leading to increased serum levels and risk of toxicity.
  • mTOR Inhibitors (e.g., Everolimus): Increased risk of Angioedema.

Mechanism of Action

Biopril, containing lisinopril, functions as an angiotensin-converting enzyme (ACE) inhibitor. Its primary biological target is the zinc-containing ACE enzyme located predominantly on the luminal surface of vascular endothelial cells.

Lisinopril interacts with ACE as a competitive inhibitor, occupying the active site and preventing the conversion of the inactive decapeptide angiotensin I into the potent vasoconstrictor angiotensin II. This inhibition directly modulates the renin-angiotensin-aldosterone system (RAAS).

Downstream, the reduction in circulating angiotensin II levels leads to two key intracellular consequences: vasodilation in arterioles and venules due to decreased AT1 receptor stimulation on smooth muscle cells, and reduced aldosterone secretion from the adrenal cortex. Reduced aldosterone decreases sodium and water reabsorption in the renal collecting ducts.

Simultaneously, ACE inhibition impedes the enzymatic degradation of the vasodilator peptide bradykinin, amplifying its action. The system-level physiological consequence of these pathways is a modulation of the cardiovascular system, resulting in decreased systemic vascular resistance and reduced circulating blood volume.

Dosage and Administration Information

How to Use Biopril: Official Administration Guidelines

Biopril (Lisinopril) is administered as a single daily dose via the oral route. The medicine is available as an oral tablet (in strengths up to 40 mg) and a 1 mg/mL oral solution. Proper use is defined by a titration schedule, specific timing rules, and adjustments based on the patient's clinical profile.


Official Dosing and Administration

Indication Initial Dose (Oral, Once Daily) Maximum Labeled Dose Use Duration
Hypertension 10 mg (non-diuretic therapy) 80 mg Long-term maintenance
Heart Failure 2.5 mg to 5 mg 40 mg Long-term maintenance
Acute MI 5 mg (within 24 hours of onset) 10 mg (daily maintenance) Minimum 6 weeks

Note: The typical daily maintenance dose for hypertension is 20 mg to 40 mg.


Key Procedural Instructions

  • Timing: The dose should be taken at approximately the same time each day, and intake is permitted with or without food.
  • Titration: Dosage adjustments for chronic conditions are typically performed gradually over several weeks (e.g., at intervals of no less than two weeks in heart failure).
  • Diuretic Use: If a patient is receiving diuretic therapy, the diuretic should ideally be discontinued 2 to 3 days prior to initiating Biopril to reduce the risk of acute effects, or the initial Biopril dose must be reduced to 5 mg.
  • Renal Impairment: Dosing is strictly based on renal function. For patients with creatinine clearance between 10 to 30 mL/min, the usual initial dose is halved. For severe impairment or patients on dialysis (CrCl < 10 mL/min), the starting dose is 2.5 mg once daily.
  • Pediatric Use: For pediatric patients (aged 6 years and older) with hypertension, dosing is weight-based, starting at 0.07 mg/kg (up to a maximum initial dose of 5 mg).

Clinical protocols involve a structured titration phase starting with low, individualized doses, where initial adjustment is governed by volume status and renal function, standardizing the initiation and long-term maintenance of the therapy.

Recent Clinical Evidence

Biopril: Recent Clinical Evidence

Biopril is a medication belonging to the class of Angiotensin-Converting Enzyme (ACE) inhibitors, which are established agents for cardiovascular conditions. Clinical research has primarily focused on its effects in managing hypertension (high blood pressure) and heart failure.

Evidence in Hypertension

Large-scale randomized controlled trials (RCTs) examining the ACE inhibitor class, including Biopril, have demonstrated an association between treatment and a statistically significant reduction in systolic and diastolic blood pressure across diverse populations. This blood pressure reduction is considered crucial for helping to minimize the long-term risk of adverse cardiovascular and cerebrovascular events.

Evidence in Heart Failure

In patients diagnosed with heart failure and reduced ejection fraction, clinical studies suggest that the addition of an ACE inhibitor, such as Biopril, to a standard regimen may be associated with improved outcomes and reduced rates of hospitalization. The mechanism of action is thought to involve lessening the workload on the heart, leading to improved cardiac efficiency.

Safety Profile Observations

The most common adverse events observed in clinical trials for ACE inhibitors include a persistent dry cough and dizziness, which may be related to low blood pressure. Elevated potassium levels in the blood (hyperkalemia) have also been reported. Rarely, a serious reaction involving swelling beneath the skin (angioedema) has occurred. All patients are advised to discuss their individual health history and potential risks with a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Biopril (FAQ)

Q: How quickly should I expect Biopril to start affecting my blood pressure?

A: Official product information indicates that a reduction in blood pressure is generally observable within one hour after taking a single dose. The maximum effect typically occurs about six to eight hours after ingestion. Achieving the full intended therapeutic effect may involve gradual dosage adjustments over a period of weeks, as noted in the drug's administration guidelines.


Q: Is it normal to feel dizzy or lightheaded after taking the first few doses of Biopril?

A: Regulatory documents list dizziness as a common side effect of Biopril. Official warnings note that the risk of symptomatic hypotension (low blood pressure) is explicitly documented to be highest when the medication is first started or after a dosage increase. This feeling of lightheadedness is a known and monitored effect.


Q: How long does the dry cough side effect typically last if I continue taking the medication?

A: The persistent dry cough is a common side effect of this class of medicines. Reports and official data indicate that if the cough is caused by Biopril, it is often reversible and may subside substantially within a period of 1 to 4 weeks following discontinuation of the medication.


Q: Why is it important to stand up slowly when getting up from a sitting or lying position while on Biopril?

A: Biopril lowers blood pressure, and official information notes that this can lead to dizziness and lightheadedness. Changing body positions slowly may help the body adjust to the blood pressure changes and reduce the chance of experiencing dizziness or lightheadedness upon standing.


Q: Is it true that Biopril can reduce the risk of heart attack and stroke?

A: The regulatory label states that lowering blood pressure with Biopril contributes to minimizing the long-term risk of adverse cardiovascular and cerebrovascular events. These events primarily include strokes and myocardial infarctions (heart attacks).


Q: What is the difference between Biopril and Biopril AM, which is a combination pill?

A: Biopril contains a single active ingredient, lisinopril, classifying it as a monotherapy drug. Combination products that pair lisinopril with a second agent, such as a diuretic (like hydrochlorothiazide), are also approved to treat high blood pressure.


Q: Can I use salt substitutes while taking Biopril?

A: Official regulatory warnings list salt substitutes containing potassium as an interacting substance. Combining them with Biopril carries a significant risk of hyperkalemia, which is an unsafe rise in potassium levels in the blood. Therefore, the use of these substitutes while taking Biopril must be approached with caution.


Q: Is Biopril a blood thinner or a diuretic (water pill)?

A: No, Biopril's active ingredient, lisinopril, is a member of the Angiotensin-Converting Enzyme (ACE) Inhibitor class of medicines. It is neither a blood thinner nor a diuretic.


Q: Is Biopril considered a long-term medication for chronic conditions?

A: Yes, according to the official dosing and administration guidelines, Biopril is indicated for the long-term maintenance treatment of chronic conditions such as hypertension (high blood pressure) and heart failure. It is designed for ongoing management of these conditions.


Q: Does Biopril affect kidney function, and should my kidneys be checked regularly?

A: Regulatory documents state that Biopril can be associated with adverse changes in renal function (kidney function). Official information indicates that for some patients, particularly those with existing risk factors, close monitoring of kidney function may be part of the therapeutic management plan.


Q: How does alcohol consumption interact with the effects of Biopril?

A: Regulatory labeling does not list a direct interaction between Biopril and alcohol. However, alcohol may potentially intensify certain side effects like dizziness or headache, which are related to the drug's blood pressure-lowering effect.


Q: Is it safe to take over-the-counter pain relievers, like NSAIDs or aspirin, with Biopril?

A: Official drug interaction warnings state that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include some common pain relievers, may reduce Biopril's effectiveness in lowering blood pressure. Co-administration can also increase the risk of renal function deterioration, particularly in the elderly or those with existing kidney issues.


Q: Can Biopril be used in children for high blood pressure?

A: Biopril is indicated for the treatment of hypertension in pediatric patients ge 6 years of age. However, the label does not establish use for children under 6 years of age, and the medication is not indicated for that age group.


Q: Does Biopril affect blood sugar levels, especially in people with diabetes?

A: Regulatory warnings indicate that taking Biopril at the same time as certain antidiabetic medicines (like insulins) can increase the risk of hypoglycemia (low blood sugar). This noted interaction may necessitate adjustments to the patient's existing regimen.


Q: What should I do if I experience nausea or stomach upset while taking Biopril?

A: Nausea is a documented adverse event, and official warnings note that severe stomach pain—especially when combined with nausea or vomiting—could potentially indicate intestinal angioedema, a rare but serious condition.


Q: Can Biopril cause insomnia or difficulty sleeping?

A: Yes, regulatory documents list insomnia (difficulty sleeping) as a less common adverse reaction associated with Biopril use.


Q: Are there certain groups of people (e.g., specific ethnicities) who are more likely to experience certain side effects like the cough or angioedema?

A: Official clinical and post-marketing data indicate that the risk of angioedema (serious swelling of the face or throat) is noted to be higher in Black patients taking ACE inhibitors compared to other populations. This is an important safety consideration documented in regulatory information.


Q: Does Biopril affect liver function?

A: Though rare, cases of severe hepatic failure (liver injury) have been reported with Biopril. Official regulatory information states that the development of yellowing of the skin or eyes (jaundice) or marked elevation of liver enzymes may necessitate discontinuation of the medication.


Q: What is the typical timeframe for Biopril to reach its full effect in controlling blood pressure?

A: The process for achieving the full intended therapeutic effect of Biopril for chronic conditions often involves a period of gradual dosage adjustment. Official dosing schedules indicate that dosage changes are often made at intervals of no less than two weeks until the optimal blood pressure goal is reached.


Q: Can Biopril cause a rash or skin irritation?

A: Yes, regulatory documents list rash as a less common adverse reaction to Biopril.


Q: Is it a common practice to combine Biopril with a diuretic?

A: Yes, the combination of Biopril with a diuretic (or 'water pill') is a common medical practice. Approved combination products are available, and the official dosing instructions include specific adjustments for patients who are already receiving diuretic therapy.


Q: Does Biopril affect sexual ability or desire?

A: Regulatory documents list impotence (inability to have or keep an erection) as a less common adverse reaction associated with Biopril.


Q: Why might Biopril be considered a first-choice treatment for high blood pressure?

A: Clinical guidelines, which inform regulatory practice, often recommend ACE inhibitors like Biopril as first-line agents for managing hypertension. This is based on their proven effectiveness in lowering blood pressure and their long-term benefit for cardiovascular health.


Q: If I have a persistent side effect, what are the general alternative drug classes that might be used instead of Biopril?

A: If a persistent side effect occurs, alternatives often include other classes of blood pressure medications. General alternatives mentioned in clinical guidance include Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, and other types of Diuretics.

How should Biopril be stored and disposed of?

How to Store and Dispose of Biopril?

Regulatory labeling establishes mandatory requirements for the storage, handling, and disposal of Biopril to ensure product stability and safety.

Official Storage Requirements

Storage Component Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Prohibitions Do not freeze. Do not store above 30 C.
Protection Keep in the original, tightly closed container and protect from moisture and light.
Child Safety Mandatory to keep out of the reach of children.

Official Disposal Instructions

Unused or expired Biopril must be disposed of according to federal, state, and local pharmaceutical waste regulations. Regulatory guidelines generally prohibit placing the medicine in household trash or flushing it down the toilet. Disposal via an authorized drug take-back program or official collection point is recommended to comply with environmental and safety standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biopril found in:

A-Z Index: